Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of the cervix. Cervical cancer is generally preceded by Cervical Intraepithelial Neoplasia (CIN). Nearly all cervical cancer cases (>90%) have been linked with HPV infection, with identification of 14 high-risk HPV (hrHPV) genotypes linked to cervical cancer.
Typically, squamous cells lining the cervix respond to exposure to HPV infection, causing them to replicate. The extent of abnormal growth (in the pre-cancerous phase) is the basis for CIN grading, from 1 to 3, where 3 represents disorganisation through the full extent of then epithelial layer.
This report provides the current incident population for Cervical Cancer across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Netherlands, Poland, Romania, Russia, Turkey, Australia, Japan, South Korea, China, India, Argentina, Brazil, Mexico, South Africa and Saudi Arabia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Cervical Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
The following conditions are associated with cervical cancer:
• Infection with HPV genotypes 16 & 18
• Unprotected sex
• Extended use of oral contraceptives
• Impaired immunity
• Smoking
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Cervical Cancer market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Cervical Cancer and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Cervical Cancer’s Incident population.
• Identify sub-populations within Cervical Cancer which require treatment.
• Gain an understanding of the specific markets that have the largest number of Cervical Cancer patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
o Impact of HPV vaccination
o Additional data available on request
• Top-line prevalence for Cervical Cancer
• Stage of Cervical Cancer patients
• Histopathology of Cervical Cancer patients
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• HPV type and disease association with cervical cancer
• HPV vaccines currently available
• The Bethesda Classification System for cervical squamous cell dysplasia
• FIGO staging of cervical cancer
• 5-year survival rate by stage of cervical cancer
• Incidence of Cervical cancer, females (000s)
• Cervical cancer patients by FIGO stage, females (000s)
• Cervical cancer patients by histopathologic type, females (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Canada Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• France Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Germany Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Italy Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Spain Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• United Kingdom Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Netherlands Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Poland Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Romania Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Russia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Turkey Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Australia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Japan Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• South Korea Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• China Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• India Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Argentina Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Brazil Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Mexico Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• South Africa Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Cervical Cancer by 5-yr age cohort, females (000s)
List of Figures
• Profiles of Cervical cancer incidence by age
• Incidence of Cervical cancer by country
• Expected impact in Cervical cancer incidence due to HPV immunisation (UK)
